Crystalline Psilocybin Polymorph Control for Scalable High-Purity Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing psilocybin are limited in scale, purity, and consistency, making it challenging to produce large batches suitable for clinical trials and commercial use, particularly for the treatment of treatment-resistant depression.
Innovation Solution
Development of crystalline psilocybin in specific polymorphic forms, such as Polymorph A and Polymorph A', characterized by distinct XRPD and DSC patterns, ensuring high chemical purity and stability, with methods to reproduce these forms consistently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods for producing psilocybin are used, then production can be achieved, but the scale is limited and cannot meet clinical trial and commercial requirements
Solution Approach 1:
The patent modifies critical process parameters including reaction temperature, solvent composition, pH control, and crystallization conditions to enable scalable production. The optimized synthesis protocol maintains high purity while increasing batch sizes from gram-scale to kilogram-scale, directly resolving the contradiction between production scale and batch size limitations
Solution Approach 2:
The patent utilizes controlled crystallization phase transitions to produce consistent polymorphic forms (Polymorph A and Polymorph A') at large scale. By controlling the phase transition during crystallization through temperature and solvent management, the process achieves both high productivity and consistent product quality suitable for clinical and commercial use
2Manufacturing precision
If existing production methods are used, then psilocybin can be produced, but chemical purity and consistency are insufficient for medical use
Solution Approach 1:
The patent incorporates preliminary purification steps and controlled crystallization protocols before final product isolation. By pre-establishing pure intermediates and controlling the crystallization environment, the process ensures high chemical purity and consistent polymorphic form across batches, resolving the contradiction between manufacturing precision and reliability
Solution Approach 2:
The patent implements analytical monitoring and quality control measures at multiple stages of the synthesis process. By using feedback from analytical data to adjust process parameters, the method maintains consistent chemical purity and polymorphic form, ensuring batch-to-batch reliability required for medical applications
3Adaptability or versatility
If psilocybin is produced for clinical trials, then treatment of depression can be pursued, but production must meet strict purity and consistency standards
Solution Approach 1:
The patent optimizes process parameters to produce consistent polymorphic forms (Polymorph A and Polymorph A') with defined XRPD and DSC characteristics. By controlling crystallization parameters and purification conditions, the process meets the strict manufacturing precision requirements for medical use while maintaining adaptability for clinical trials and commercial deployment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves chemically pure, stable, and consistently reproducible large-scale production of psilocybin, suitable for medical use, particularly in treating depression, with batch-to-batch consistency and high purity.
Implementation Method 1
Development of crystalline psilocybin in specific polymorphic forms, such as Polymorph A and Polymorph A', characterized by distinct XRPD and DSC patterns
Data Source
AI summary
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.